1. Market Research
  2. > Biotechnology
  3. > Medical Biotechnology Market Trends
Viral Vectors Market by Application and Geography - Forecast and Analysis 2020-2024

Viral Vectors Market by Application and Geography - Forecast and Analysis 2020-2024

  • November 2019
  • 154 pages
  • ID: 5829118
  • Format: PDF
  • By Infiniti Research Limited

Summary

Table of Contents

Global Viral Vectors Market: About this market
This viral vectors market analysis considers sales from both gene therapy and vaccines applications. Our study also finds the sales of viral vectors in Asia, Europe, North America, and ROW. In 2019, the gene therapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as easy purification into high titers to mediate targeted gene delivery and its prolonged gene expression with nominal side effects will play a significant role in the gene therapy segment to maintain its market position. Also, our global viral vectors market report looks at factors such as rising prevalence of chronic diseases, increasing use of viral vectors to develop gene therapies and vaccines, and growing funding on and investments in gene therapies and vaccines. However, challenges associated with production and manufacturing of viral vectors, presence of stringent regulatory policies, and risks associated with viral vectors may hamper the growth of the viral vectors industry over the forecast period.

Global Viral Vectors Market: Overview
Rising prevalence of chronic disease
The development of therapies using viral vectors is in high demand due to the growing incidence of various life-threatening diseases such as diabetes, heart disease, HIV, cancer, and hemophilia A. Researchers are using viral vectors to develop curative therapies for cancer diseases such as bladder cancer, melanoma of the skin, lung and bronchus cancer, and other types of cancers. This is because viral vectors are a promising tool for the development of vaccines and gene therapy. Thus, the rising prevalence of chronic disease will lead to the expansion of the global viral vectors market at a CAGR of over 18% during the forecast period.
Emergence of novel technologies to manufacture viral vectors
The use of viral gene transfer vectors has increased owing to the approval of therapies, the initiation of late-stage clinical trials for the treatment of genetic disorders and multiple forms of cancer, and the need for the prevention of infectious diseases through vaccination. With an increased interest in and the widespread adoption of viral vectors by biopharmaceutical industries, there is a need to engineer safe and efficacious vectors and develop robust, scalable, and cost-effective production platforms for industrialization. Furthermore, adeno-associated virus vectors are among most commonly applied virus vectors for in vivo gene therapy as they can transduce non-dividing and dividing cells resulting in long-term and robust transgene expression. This development is expected to have a positive impact on the overall market growth.

Competitive Landscape
With the presence of a few major players, the global viral vectors market is concentrated. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading viral vectors manufacturers, that include Asklepios BioPharmaceutical Inc., Batavia Biosciences BV, Cobra Biologics Ltd., Creative Biogene, FinVector Oy, Lonza Group Ltd., Merck KGaA, Novasep Holding SAS, Oxford Biomedica Plc, and Thermo Fisher Scientific Inc.
Also, the viral vectors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Global Gene Therapy Partnering Terms and Agreements 2014 to 2019

Global Gene Therapy Partnering Terms and Agreements 2014 to 2019

  • $ 2995
  • December 2019

The Global Gene Therapy Partnering Agreements 2014-2019 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.Trends ...

Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Pipeline Review, H2 2019

Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Mucopolysaccharidosis III (MPS III) (Sanfilippo ...

Glucosylceramidase - Pipeline Review, H2 2019

Glucosylceramidase - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Glucosylceramidase - Pipeline Review, H2 2019SummaryGlucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase o ...


ref:plp2019

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on